Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literatureReport as inadecuate




Rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in FLT3-ITD-positive patients unfit for intensive treatment: two cases and review of the literature - Download this document for free, or read online. Document in PDF available to download.

Journal of Hematology and Oncology

, 6:39

First Online: 11 June 2013Received: 09 April 2013Accepted: 24 May 2013DOI: 10.1186-1756-8722-6-39

Cite this article as: Wolleschak, D., Schalk, E., Krogel, C. et al. J Hematol Oncol 2013 6: 39. doi:10.1186-1756-8722-6-39

Abstract

Treatment of acute myeloid leukemia remains a therapeutic challenge. Even in younger patients with a low rate of co-morbidities less than 50% of patients can be cured. For older patients or patients with significant co-morbidities, the situation appears even worse. In patients not eligible for intensive treatment approaches - e.g. due to underlying medical conditions - therapeutic approaches remain almost exclusively palliative. However, even with less intense treatment approaches, temporary remission can be achieved and this contributes to prolonged survival and improved quality of life of the respective patient. Targeted therapies have been widely used as palliative treatment in- and outside clinical trials as single agents. Combination with low-dose cytarabine LDAC potentially improves remission rates and can be safely administered in an outpatient setting.

Previous studies showed that additive hematologic toxicity of combinatory therapeutic approaches may arise from simultaneous treatment e.g. chemotherapy plus targeted therapies. However, sequential therapies have already proven their feasibility in clinical trials. Here, we report two cases of rapid induction of complete molecular remission by sequential therapy with LDAC and sorafenib in patients unfit for intensive chemotherapy without significant long-term toxicity.

KeywordsAML Sorafenib Small molecule LDAC Targeted therapy Electronic supplementary materialThe online version of this article doi:10.1186-1756-8722-6-39 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Author: Denise Wolleschak - Enrico Schalk - Christian Krogel - Tina M Schnoeder - Helga Luehr - Kathleen Jentsch-Ullrich - Thomas 

Source: https://link.springer.com/







Related documents